Efficacy of oral safflower oil in treatment of melasma
- Conditions
- Melasma.ChloasmaL81.1
- Registration Number
- IRCT20150825023753N15
- Lead Sponsor
- Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Diagnosis of melasma by a dermatologist
The patient is bound to cooperate for regular use of the studied drug and refer at the appointed time
Having informed and written consent to participate in the study
Satisfaction with not using out-of-protocol therapies
Pregnant and lactating women
Individuals with other organ disorders (cancers, liver, kidney)
History of hypersensitivity reaction to safflower seeds
39/5000Patient dissatisfaction to continue the project for any reason
Individuals with diabetes
Taking skin lightening medications in the last two weeks
Taking hormonal contraceptives and other medications that cause melasma
Taking anticoagulants (aspirin, Plavix, warfarin)
Individuals with coagulation diseases
History of hypersensitivity to safflower seeds
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The rate of melasma discoloration. Timepoint: Measurements are taken at the start of the study, one month and two months after the start of the study. Method of measurement: Using Visioface 1000D and The Melasma Area and Severity Index (MASI).
- Secondary Outcome Measures
Name Time Method Quality of life of patients with melasma. Timepoint: This variable is measured at the beginning of the study and two months later. Method of measurement: The Melasma Quality of Life scale (MELASQOL).